Published Date: 02 Mar 2023
Understanding the Reasons and Issues for Low NMOSD Activity Rates: Farrah Mateen, MD, PhD
Read Full NewsBefore you freeze a skin lesion, ask yourself whether you really know what it is. Here are four signs you should biopsy instead of freeze.
EyePoint said its experimental drug missed the main goal in a late-stage trial as a few patients lost vision from causes unrelated to the targeted disease, sending its...
The FDA has approved a radioactive agent for use in brain scans to help assess patients for Alzheimer's disease.
An automated MRI measure shows that each extra year the brain appears older than chronologic age is linked to increased dementia risk, especially in patients with subjective cognitive concerns.
The Ebola outbreak in Democratic Republic of Congo has killed 2,325 people, government data showed on Sunday, surpassing the toll from the 2018-2020 outbreak to become the...
A West Nile virus infection has been detected in the Netherlands for the first time since 2020, Dutch public health institution RIVM said on Monday.
A shift in prescribing practices at a Seattle sexual health clinic corresponded with a notable decline in recurrent rectal chlamydia cases among men who have sex with men.
1.
Don't Call It Cancer; Clues to 'Exceptional' Responses; More Predictions for 2025
2.
The September 2018 issue of Medical Bulletin.
3.
US to Loosen Marijuana Rules in Major Shift for $47 Billion Industry
4.
For the treatment of paroxysmal nocturnal hemoglobinuria, the FDA has approved an oral factor B inhibitor.
5.
CAR-T Induces Deep, Durable Remission in Smoldering Myeloma
1.
Tumor Microenvironment Reprogramming Through Stromal Modulation
2.
The benefits and risks of taking fludrocortisone for adrenal insufficiency
3.
AI and Optical Advances: Evolving Blood Cell Morphology Observation in Hematology
4.
Advanced Advances in Oncology for Healthcare Excellence
5.
Harnessing Cuproptosis: A Novel Nanomedicine Strategy for Triple-Negative Breast Cancer
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
1.
The Landscape of First-Line Treatment for Urothelial Carcinoma- The Conclusion
2.
Pazopanib Takes Center Stage in Managing Renal Cell Carcinoma - Part V
3.
Molecular Contrast: EGFR Axon 19 vs. Exon 21 Mutations - Part V
4.
Efficient Management of First line ALK-rearranged NSCLC - Part VI
5.
The Landscape of First-Line Treatment for Urothelial Carcinoma- Further Discussion
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation